SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals informs about newspapers clippings

06 Nov 2024 Evaluate
With reference to letter No. JPL/CS/2140/2024 dated 5th November, 2024, Jenburkt Pharmaceuticals has informed that it enclosed clippings of two Newspapers, The Free Press Journal, Mumbai (English) and  Navshakti, Mumbai (Marathi) dated 6th November, 2024 containing the standalone Unaudited Financial Results of the Company for the quarter and half year ended on 30th September, 2024. 

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1025.60 6.35 (0.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×